跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
連結會在新分頁中打開
English
中文
在 臺北醫學大學 搜尋內容
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
查看斯高帕斯 (Scopus) 概要
許 永和
教授
,
腎臟內科
合聘教授
,
臨床醫學研究所
成員
,
臺北醫學大學泌尿腎臟研究中心
成員
,
臺北醫學大學生醫器材研究中心
主治醫師
,
臺北市立萬芳醫院
成員
,
臺北醫學大學人工智慧醫療研究中心
https://orcid.org/0000-0002-6090-3418
電子郵件
yhhsu
tmu.edu
tw
,
88347
w.tmu.edu
tw
h-index
3260
引文
32
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1991 …
2025
每年研究成果
概覽
指紋
網路
專案
(22)
研究成果
(143)
資料集
(3)
類似的個人檔案
(12)
指紋
查看啟用 Yung-Ho Hsu 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Acute Kidney Failure
15%
Adverse Outcome
10%
All Cause Mortality
23%
Angiotensin Receptor Antagonist
15%
Antihypertensive Agent
10%
Arteriovenous Fistula
22%
Carbon Monoxide Poisoning
8%
Cardiovascular Disease
19%
Cardiovascular Mortality
9%
Case-Control Study
8%
Cerebrovascular Accident
8%
Chronic Kidney Failure
100%
Cinacalcet
13%
Cohort Study
17%
Deterioration
13%
Diabetes Mellitus
13%
Dipeptidyl Carboxypeptidase Inhibitor
15%
Doxorubicin
14%
End Stage Renal Disease
26%
Endothelin 1
11%
Epidermal Growth Factor Receptor
8%
Fibrosis
15%
Fucoidan
14%
Fucoxanthin
8%
Gentamicin
27%
Hemodialysis
70%
Hypertension
16%
Hypoxia Inducible Factor 1
8%
Inflammasome
14%
Inflammation
10%
Kidney Disease
18%
Leptin
8%
Loop Diuretic Agent
8%
Monotherapy
9%
Nanoparticle
8%
Nephrotoxicity
15%
Parathyroid Hormone
14%
Peritoneal Fibrosis
8%
Peroxisome Proliferator Activated Receptor
14%
Prostacyclin
18%
Protein Kinase B
21%
Randomized Controlled Trial
9%
Rat
46%
Reactive Oxygen Metabolite
17%
Replacement Therapy
11%
Sodium Ion
8%
Stevioside
8%
Tetramethylpyrazine
8%
Therapeutic Effect
14%
Urotensin II
8%
Medicine and Dentistry
4 Iodo 2,5 Dimethoxyamphetamine
8%
ACE Inhibitor
6%
Acute Kidney Injury
5%
Adverse Outcome
8%
All Cause Mortality
9%
Angiotensin Receptor Antagonist
6%
Arteriovenous Fistula
22%
Cardiology
5%
Cardiovascular Disease
18%
Cardiovascular Mortality
5%
Cardiovascular Risk
5%
Catenin
5%
Chronic Kidney Disease
51%
Cohort Analysis
19%
Congestive Heart Failure
6%
Cross Sectional Study
6%
Deterioration
9%
Diabetes
5%
Diabetes Mellitus
8%
Division
8%
End Stage Renal Disease
18%
Hemodialysis
41%
Internal Medicine
17%
Kidney Function
13%
Logistic Regression Analysis
5%
Maturation
5%
Meta-Analysis
8%
Metabolic Syndrome
8%
Mortality Rate
6%
Nephrology
14%
Nephropathy
20%
Observational Study
5%
Odds Ratio
6%
Peritoneal Dialysis
14%
Prevalence
10%
Programmed Cell Death
5%
Proportional Hazards Model
6%
Protein Kinase B
5%
Randomized Controlled Trial
8%
Systolic Blood Pressure
5%
Nursing and Health Professions
Acute Kidney Failure
5%
Adverse Outcome
8%
All Cause Mortality
6%
Body Mass
9%
C Reactive Protein
5%
Cardiovascular Disease
16%
Chronic Kidney Failure
40%
Cohort Analysis
7%
Confidence Interval
6%
Cross-Sectional Study
11%
Deterioration
8%
Education
9%
End Stage Renal Disease
13%
Hemodialysis
36%
Hyperhomocysteinemia
5%
Insulin Resistance
10%
Kidney Disease
7%
Meta Analysis
8%
Muscle Mass
8%
Prevalence
8%
Propensity Score
10%
School Health Service
13%
Treatment Outcome
5%
